other material
confidence high
sentiment positive
materiality 0.85
Edgewise reports positive Phase 2 data for EDG-7500 in HCM; 71% LVOT-G reduction at rest
Edgewise Therapeutics, Inc.
- Obstructive HCM: 100 mg dose achieved mean 71% reduction in resting LVOT-G and 58% in provokable gradients over 4 weeks.
- NT-proBNP reduced 62% in obstructive and 42% in nonobstructive HCM at 100 mg; KCCQ-OSS improved 23 and 17 points respectively.
- No LVEF <50%; two participants had serious AF requiring cardioversion; one discontinuation due to dizziness.
- Part D 12-week data expected H2 2025; Phase 3 CIRRUS-HCM trial initiation planned for H1 2026.